Tigo Energy Delivers Scalable Insights on EI Platform for High-Growth, Multi-Site Solar Installers
9.7.2024 16:00:00 EEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today unveiled a new set of powerful and customizable features of the Tigo Energy Intelligence (EI) Platform. With a newly retooled, upgraded, and tiered approach to delivering the right solar monitoring and insights, even small and mid-sized installation companies can manage their growing solar customer portfolios sustainably. These platform enhancements come online as the U.S. installed base of solar surpasses the 5 million solar installations threshold and the industry considers how it will manage the O&M work as those numbers double by 2030 and triple by 2034.
The Tigo EI Platform now offers upgrade options that deliver even more of the right information at the right time via a user-friendly interface to installers, asset managers, and down to the individual system owner. Most notably for rapidly scaling installers, EPCs, and O&M providers, the new EI Professional package provides a centralized view of critical health and performance data of all systems under management. Beyond a scalable monitoring experience and a simple, flat-price model, the EI Professional package includes:
- one-click enrollment for company-wide, unlimited-seat subscription access covering all systems under management,
- a portfolio-wide dashboard with a prioritized view into critical data, such as health status, production, performance, equipment status, location data, and commissioning time tracking, and
- time-saving features including advanced tagging, grouping, and site filtering for improved management, maintenance, optimization, and trend analysis.
Solar installers use the Tigo EI Platform to gain improved insights into installation status, decrease O&M costs, and monitor energy generation and system performance. The standard system-by-system monitoring view, now named EI Basic, remains free of charge, and includes module-level resolution and insight into third-party hardware. More advanced monitoring and analytics tools, historical data, and minute-level monitoring resolution, among others, are available via a simple, in-platform upgrade to EI Premium.
“As we watch the number, size, and complexity of the residential and commercial systems we deploy increase, we found that the only way to scale was with a comprehensive way to monitor, diagnose, and optimize those systems,” said Garrett Brandt, owner at Radius Energy. “When you consider the cost of even a single truck roll or the opportunity cost of a one-week delay in getting an invoice out post-commissioning, a paid subscription to avoid either makes sense right away. The features now available via the Tigo EI Platform don’t just add value in terms of savings but represent new opportunities for us on the installer side.”
Installer training materials for the EI Platformare now available in the Tigo Academy. Tigo Academy offers new and existing customers and installers an efficient way to learn about Tigo software through hands-on demonstrations and tutorials on how to leverage Tigo software for optimal system performance and customer satisfaction.
“To stay competitive, installers have to become more agile while providing more post-installation services, which is why Tigo has developed increasingly sophisticated options in the EI Platform that deliver the right management tools to the variety of customers we serve,” said Archie Roboostoff, vice president of software, at Tigo Energy. “Software plays an increasingly important role in ensuring that solar deployments reach peak performance while continuously analyzing trends to see where improvements can be made. The EI Platform is designed to identify system issues before production is impacted. System owners expect quality and reliability, and the EI Platform helps to deliver both.”
To learn more about the Tigo EI Platform, including the standard capabilities of EI Basic and the features and subscription pricing for EI Premium and EI Professional, please visit the EI features page at https://www.tigoenergy.com/ei/pricing. Tigo installers are also invited to take advantage of promotional trial access to EI Professional for the month of July, which is available via web browser on the Tigo EI Platform: https://ei.tigoenergy.com/
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709862359/en/
Contacts
Technica Communications
Cait Caviness
Email: tigoenergy@technica.inc -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftigoenergy%40te
chnica.inc&esheet=54092036&newsitemid=20240709862359&lan=en-US&anchor=tigoenergy
%40technica.inc&index=8&md5=f7a31dc632c64a578651acfbf13ae9c6
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom